Recombinant human annexin A5 inhibits proinflammatory response and improves cardiac function and survival in mice with endotoxemia

Critical Care Medicine

Volumn 42, Issue 1, 2014, Pages

  Arnold, Paul ^a   Lu, Xiangru ^a,b   Amirahmadi, Fatemeh ^a   Brandl, Katharina ^c   Arnold, J Malcolm O ^a   Feng, Qingping ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

annexin A5; cardiac function; sepsis; tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT HUMAN ANNEXIN A5; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTOXEMIA; ENZYME ACTIVATION; EXPERIMENTAL STUDY; HEART FUNCTION; HEART MUSCLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SURVIVAL; TREATMENT RESPONSE;

EID: 84891501511     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182a63e01     Document Type: Article

References (44)

1. Global Sepsis Alliance: International organizations declare sepsis a global medical emergency. 2010. Available at: http://www.globalsepsisalliance. org/about/merinoff/press-release.pdf. Accessed March 15, 2012
2. Canadian Institute for Health Information (CIHI): In Focus: A National Look at Sepsis. Ottawa, Canada, CIHI, 2009
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
4. Hall MJ, Williams SN, DeFrances CJ, et al: NCHS Data Brief: Inpatient Care for Septicemia or Sepsis: A Challenge for Patients and Hospitals. National Center for Health Statistics, MD; Number 62, June 2011. Available at: http://www.cdc.gov/nchs/data/databriefs/db62.htm. Accessed March 30, 2012
5. Kumar G, Kumar N, Taneja A, et al: Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011; 140:1223-1231
6. Yeh RW, Sidney S, Chandra M, et al: Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362:2155-2165
7. Mitchell JA, Ryffel B, Quesniaux VF, et al: Role of pattern-recognition receptors in cardiovascular health and disease. Biochem Soc Trans 2007; 35:1449-1452
8. Zhang T, Feng Q: Nitric oxide and calcium signaling regulate myocardial tumor necrosis factor-expression and cardiac function in sepsis. Can J Physiol Pharmacol 2010; 88:92-104
9. Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242
10. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280-287
11. Natanson C, Eichenholz PW, Danner RL, et al: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823-832
12. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 1998; 274:R577-R595
13. Toussaint S, Gerlach H: Activated protein C for sepsis. N Engl J Med 2009; 361:2646-2652
14. Gentry CA, Gross KB, Sud B, et al: Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009; 37:19-25
15. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
16. US Food and Drug Administration: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit. 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm277114htm. Accessed November 25, 2011
17. Gerke V, Moss SE: Annexins: From structure to function. Physiol Rev 2002; 82:331-371
18. Reutelingsperger CP, van Heerde WL: Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997; 53:527-532
19. Markoff A, Bogdanova N, Knop M, et al: Annexin A5 interacts with polycystin-1 and interferes with the polycystin-1 stimulated recruitment of E-cadherin into adherens junctions. J Mol Biol 2007; 369:954-966
20. Bell JK, Mullen GE, Leifer CA, et al: Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003; 24:528-533
21. Peng T, Lu X, Lei M, et al: Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival during acute endotoxemia in mice. Cardiovasc Res 2003; 59:893-900
22. Xiang FL, Lu X, Hammoud L, et al: Cardiomyocyte-specific overexpression of human stem cell factor improves cardiac function and survival post myocardial infarction in mice. Circulation 2009; 120:1065-1074
23. Zhang T, Lu X, Li J, et al: Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemia. Basic Res Cardiol 2012; 107:254
24. Peng T, Lu X, Feng Q: Pivotal role of gp91phox-containing NADH oxidase in lipopolysaccharide-induced tumor necrosis factoralpha expression and myocardial depression. Circulation 2005; 111:1637-1644
25. Zhang T, Lu X, Beier F, et al: Rac1 activation induces tumour necrosis factor-expression and cardiac dysfunction in endotoxemia. J Cell Mol Med 2011; 15:1109-1121
26. Brandl K, Glück T, Hartmann P, et al: A designed TLR4/MD-2 complex to capture LPS. J Endotoxin Res 2005; 11:197-206
27. Kopp A, Bala M, Buechler C, et al: C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology 2010; 151:5267-5278
28. Rand JH, Wu XX, Lin EY, et al: Annexin A5 binds to lipopolysaccharide and reduces its endotoxin activity. MBio 2012; 3:e00292-11
29. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001; 13:85-94
30. Geoghegan-Morphet N, Burger D, Lu X, et al: Role of neuronal nitric oxide synthase in lipopolysaccharide-induced tumor necrosis factoralpha expression in neonatal mouse cardiomyocytes. Cardiovasc Res 2007; 75:408-416
31. Court O, Kumar A, Parrillo JE, et al: Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002; 6:500-508
32. Peng T, Lu X, Lei M, et al: Endothelial nitric-oxide synthase enhances lipopolysaccharide-stimulated tumor necrosis factor-alpha expression via cAMP-mediated p38 MAPK pathway in cardiomyocytes. J Biol Chem 2003; 278:8099-8105
33. Kapadia S, Lee J, Torre-Amione G, et al: Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96:1042-1052
34. Grandel U, Fink L, Blum A, et al: Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 2000; 102:2758-2764
35. Damazo AS, Yona S, D'Acquisto F, et al: Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am J Pathol 2005; 166:1607-1617
36. Peng T, Zhang T, Lu X, et al: JNK1/c-fos inhibits cardiomyocyte TNFalpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia. Cardiovasc Res 2009; 81:733-741
37. Peng T, Lu X, Feng Q: NADH oxidase signaling induces cyclooxygenase-2 expression during lipopolysaccharide stimulation in cardiomyocytes. FASEB J 2005; 19:293-295
38. Kim JH, Lee G, Cho YL, et al: Desmethylanhydroicaritin inhibits NF-kappaB-regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway. Eur J Pharmacol 2009; 602:422-431
39. Bouter A, Gounou C, Bérat R, et al: Annexin-A5 assembled into twodimensional arrays promotes cell membrane repair. Nat Commun 2011; 2:270
40. Lin MC, Ebihara S, El Dwairi Q, et al: Diaphragm sarcolemmal injury is induced by sepsis and alleviated by nitric oxide synthase inhibition. Am J Respir Crit Care Med 1998; 158:1656-1663
41. Lee WL, Liles WC: Endothelial activation, dysfunction and permeability during severe infections. Curr Opin Hematol 2011; 18:191-196
42. Römisch J, Seiffge D, Reiner G, et al: In-vivo antithrombotic potency of placenta protein 4 (annexin V). Thromb Res 1991; 61:93-104
43. Boersma HH, Kietselaer BL, Stolk LM, et al: Past, present, and future of annexin A5: From protein discovery to clinical applications. J Nucl Med 2005; 46:2035-2050
44. Boersma HH, Liem IH, Kemerink GJ, et al: Comparison between human pharmacokinetics and imaging properties of two conjugation methods for 99mTc-annexin A5. Br J Radiol 2003; 76:553-560